OPKO - Carboxyl-Terminal Peptide (CTP)

Our Carboxyl Terminal Peptide (CTP) technology is used to extend the half-lives of pharmacologically active proteins. CTP uses recombinant technology to fuse a short, naturally occurring 28 amino acid sequence (a CTP) to a pharmacologically active protein which results in slower excretion of the therapeutic protein, thus, extending the protein`s half-life. At OPKO, we are currently use CTP technology to treat growth hormone deficiency and in our Factor VIIa product for the management of hemophilia A & B.